SCHEMBL1726442

SCHEMBL1726442

COCC(C)=CO[Si](C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10409103 1.00
SCHEMBL9700025 0.83
SCHEMBL20595689 0.79
SCHEMBL9300886 0.78
SCHEMBL5167517 0.77
SCHEMBL6932758 0.73
SCHEMBL10869219 0.73
SCHEMBL9580881 0.73
SCHEMBL9152933 0.73
SCHEMBL9505385 0.72 MAPT (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3281941-B1 PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID ZENTIVA KS (CZ) 2019-07-24 EP claimed
EP-3281941-A1 PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID Zentiva K.S. (CZ) 2018-02-14 EP claimed
WO-2026099466-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2026-05-15 WO disclosed
EP-4384165-A1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS Janssen Pharmaceutica NV (BE) 2024-06-19 EP disclosed
WO-2023019094-A1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 WO disclosed
EP-4103557-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2022-12-21 EP disclosed
EP-3890738-A1 MACROCYCLIC COMPOUND AND USE THEREOF Scohia Pharma, Inc. (JP) 2021-10-13 EP disclosed
WO-2021160602-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-08-19 WO disclosed
WO-2020116660-A1 MACROCYCLIC COMPOUND AND USE THEREOF SCOHIA PHARMA, INC. (JP) 2020-06-11 WO disclosed
EP-3624797-A1 KINASE INHIBITORS AND USES THEREOF Denali Therapeutics Inc. (US) 2020-03-25 EP disclosed
EP-3281941-B1 PROCESS FOR PREPARING 2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID ZENTIVA KS (CZ) 2019-07-24 EP disclosed
WO-1992007013-A1 NOVEL SILICONE-CONTAINING POLYMERS AND OXYGEN PERMEABLE HYDROPHILIC CONTACT LENSES THEREFROM PERMEABLE TECHNOLOGIES, INC. (US) 1992-04-30 WO disclosed
WO-1992007014-A1 NOVEL SILICONE-CONTAINING ACRYLIC STAR POLYMERS, BLOCK COPOLYMERS AND MACROMONOMERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-04-30 WO disclosed
EP-0457765-A4 POSITIVE SOLID BLOCK TONER 1992-01-22 EP disclosed
EP-0457765-A1 POSITIVE SOLID BLOCK TONER. DU PONT (US) 1991-11-27 EP disclosed
WO-1990007257-A2 POSITIVE SOLID BLOCK TONER E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-07-12 WO disclosed
US-4925764-A CHARGE CONTROL AGENTS E. I. DU PONT DE NEMOURS & CO. (US) 1990-05-15 US disclosed
EP-0243120-A2 Tough flexible polymer blends E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-10-28 EP disclosed
EP-0121439-A1 Tris(dialkylamino)sulfonium bifluoride catalysts E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-10-10 EP disclosed
EP-0068887-A1 \"Living\" polymers and process for their preparation E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-01-05 EP disclosed